MarginsXMarginsX
Home › Markets › Health Care › BLRX

BioLineRx Ltd. (BLRX)

BLRX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.15
-12.61% on the day
Market cap
$5.7M
Nano cap
Revenue · 2025
$1.2M
-95.9% on 2024
Net income · 2025
-$2.0M
-171.7% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1498403/000117891326001581/0001178913-26-001581-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerBLRX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryIsrael
IPO yearNot reported by the screener
SEC CIK0001498403
SEC industry codePharmaceutical Preparations
Incorporated inIsrael

Financials · 2025

LineValue
Revenue$1.2M
Net income-$2.0M
Operating income-$10.3M
Net margin-171.7%
Operating margin-871.8%
Revenue growth-95.9%
Cash$3.3M
Total assets$40.9M
P/E (computed)Net income was not positive
P/S (computed)4.9×

Warning signs

Cash runway
4.8 months
$3.3M cash at December 31, 2025
Share count, 1 year
+16.9%
2025-03-16 to 2026-03-08 · +11215.0% over 3 years
Going-concern doubt
No
20-F filed March 23, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"Management has concluded that there is substantial doubt about our ability to continue as a going concern, which could prevent us from obtaining new financing on reasonable terms or at all."
20-F 2026-03-23
Cash and burn$3.3M cash; operating cash flow -$2.0M a quarter.Report 2025-12-31
Shares outstandingNo cover-page share count in XBRLCover page 2026-03-08
Reverse splits, 3 years1; latest 1-for-40 on 2025-01-30Source 2025-01-30
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-08-31
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKesselman & Kesselman C.P.A.s, Tel-Aviv, IsraelPCAOB Form AP 2026-04-12
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
$1.2M-$2.0M-$8.1M$3.3M$4.5M$1.2M20-F 2026-03-23
FY 2024
2024-12-31
$28.9M-$9.2M-$43.9M$10.4M$4.5M$28.9M20-F 2026-03-23
FY 2023
2023-12-31
$4.8M-$60.6M-$22.6M$4.3M$3.1M$4.8M20-F 2026-03-23
FY 2022
2022-12-31
$0-$25.0M-$26.2M$10.6M$1.5M$020-F 2025-03-31
FY 2021
2021-12-31
$0-$27.1M-$23.6M$13.0M$2.8M$020-F 2024-03-26
FY 2020
2020-12-31
Not filed-$30.0M-$23.2M$16.8M$5.8MNeeds four quarters20-F 2023-03-22
FY 2019
2019-12-31
Not filed-$25.4M-$22.7M$5.3M$8.5MNeeds four quarters20-F 2022-03-16
FY 2018
2018-12-31
Not filed-$23.0M-$24.2M$3.4M$8.7MNeeds four quarters20-F 2021-02-23

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-10-02
Latest annual report20-F2026-03-23
Latest quarterly / interim6-K2026-11-16

Source: SEC EDGAR submissions feed, 619 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-24.0%
1 month-40.1%
3 months-52.2%
Year to date-53.1%
1 year-62.5%
From 52-week high-65.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ALZNAlzamend Neuro Inc.$1.18-4.84%$5.7M
APREAprea Therapeutics Inc.$0.4063-2.38%$5.8M
ACXPAcurx Pharmaceuticals Inc.$0.9350-2.60%$5.7M
LTRNLantern Pharma Inc.$0.3890-10.18%$5.8M
FBLGFibroBiologics Inc.$0.9034-2.00%$6.1M
JAGXJaguar Health Inc.$0.3864-7.74%$5.2M
TOVXTheriva Biologics Inc.$0.1400-2.85%$6.4M
CNSPCNS Pharmaceuticals Inc.$3.48+20.42%$5.1M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier